Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in investor meetings at ...

The Washington Mystics have a new jersey sponsor for the 2025 season. It's a local company that's made a big sports marketing ...

Vanda Pharmaceuticals (NASDAQ:VNDA) is scheduled to announce Q1 earnings results on Wednesday, May 7th, after market close.

The consensus rating for Vanda Pharma is Buy, based on 2 analyst ratings. With an average one-year price target of $20.0, ...

VANDA PHARMACEUTICALS ($VNDA) posted quarterly earnings results on Wednesday, May 7th. The company reported earnings of -$0.50 per share, beating estimates of -$0.61 ...

Analysts have given Lexicon Pharmaceuticals a total of 5 ratings, with the consensus rating being Buy. The average one-year ...

WASHINGTON, May 7, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2025. "Vanda has ...

Good afternoon, and welcome to the Quarter One 2025 Vanda Pharmaceuticals Incorporated Earnings Conference Call. I am Franz, and I will be the operator assisting you today. All lines have been ...

The Washington Capitals announced additional initiatives for the Eastern Conference Second Round of the Stanley Cup Playoffs ...

Vanda Pharma (NASDAQ:VNDA) is preparing to release its quarterly earnings on Wednesday, 2025-05-07. Here's a brief overview of what investors should keep in mind before the announcement.

CFO Kevin Moran reported Q1 2025 revenues of $50 million, a 5% increase year-over-year, attributed to Fanapt’s growth. Fanapt net product sales were $23.5 million, and HETLIOZ sales were $20.9 million ...